Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16930467 | 0.81 | LTB4R (0.41) | MMELTB4RLTB4R2FFAR4FASN | |
| SCHEMBL16939248 | 0.78 | MME (0.35) | MMELTB4RLTB4R2FFAR4FASN | |
| SCHEMBL16941038 | 0.77 | LTB4R (0.36) | MMELTB4RLTB4R2FFAR4FASN | |
| SCHEMBL16939238 | 0.77 | MME (0.36) | MMEFFAR4FASN | |
| SCHEMBL16939705 | 0.71 | FASN (0.35) | MMEFFAR4FASN | |
| SCHEMBL16930421 | 0.69 | LTB4R (0.39) | MMELTB4RLTB4R2FFAR4FASN | |
| SCHEMBL16939708 | 0.69 | MME (0.36) | MMEFFAR4FASN | |
| SCHEMBL20363548 | 0.69 | MME (0.36) | MMEFFAR4FASN | |
| SCHEMBL24381038 | 0.67 | MME (0.36) | MMELTB4RLTB4R2FFAR4FASN | |
| SCHEMBL19190430 | 0.67 | MME (0.37) | MMELTB4RLTB4R2FFAR4FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-10005740-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9839639-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9783507-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9593110-B2 | Neprilysin inhibitors | Theravence Biopharma R&D IP, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-9585882-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150209352-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885LTB4R 926/4885LTB4R2 1285/4885 |
| US-10005740-B2 | Neprilysin inhibitors | MME, REN, AGTR1 | MME 1/4885LTB4R 1171/4885LTB4R2 2001/4885 |
| US-20150209352-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885LTB4R 926/4885LTB4R2 1285/4885 |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885LTB4R 1171/4885LTB4R2 2001/4885 |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885LTB4R 1171/4885LTB4R2 2001/4885 |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885LTB4R 1171/4885LTB4R2 2001/4885 |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885LTB4R 926/4885LTB4R2 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.